Literature DB >> 1703026

Role of central tachykinin peptides in cardiovascular regulation in rats.

Y Takano1, A Nagashima, T Hagio, K Tateishi, H Kamiya.   

Abstract

The mechanisms of action of tachykinin peptides thought to be involved in central cardiovascular regulation were examined. Intracerebroventricular injections (i.c.v.) of tachykinin peptides caused dose-dependent increases in blood pressure and heart rate. The pressor responses to substance P (SP) (10 micrograms, i.c.v.) and neurokinin A (NKA) (10 micrograms, i.c.v.) were blocked by peripheral administration of pentolinium or phentolamine, and partially attenuated by adrenalectomy. In contrast, the only initial pressor response to the neurokinin B (NKB) analogue senktide (10 micrograms, i.c.v.) was blocked by pentolinium or phentolamine. The pressor response to senktide was inhibited by pretreatment with a vasopressin V1 receptor antagonist (d(CH2)5OMe(Tyr)AVP) (10 micrograms/kg, i.v.), and senktide (10 micrograms, i.c.v.) caused an increase in plasma vasopressin level. However, the vasopressin antagonist did not influence the SP- and NKA-induced pressor responses. These results suggest that central SP and NKA increase the blood pressure and heart rate via sympathetic nerve activity, whereas central NKB increases the blood pressure mainly via release of vasopressin from the hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1703026     DOI: 10.1016/0006-8993(90)91662-z

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

2.  Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.

Authors:  P Picard; R Couture
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

3.  Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

Authors:  P Picard; L Chrétien; R Couture
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

4.  Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.

Authors:  J Culman; B Wiegand; H Spitznagel; S Klee; T Unger
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

5.  Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.

Authors:  C Tschöpe; P Picard; J Culman; A Prat; K Itoi; D Regoli; T Unger; R Couture
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

6.  Upregulation of tachykinin NK-1 and NK-3 receptor binding sites in the spinal cord of spontaneously hypertensive rat: impact on the autonomic control of blood pressure.

Authors:  Frank Cloutier; Brice Ongali; Kathleen Deschamps; Jonathan Brouillette; Witold Neugebauer; Réjean Couture
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

7.  Nitric oxide is a mediator of tachykinin NK3 receptor-induced relaxation in rat mesenteric artery.

Authors:  A Mizuta; Y Takano; K Honda; R Saito; T Matsumoto; H Kamiya
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.

Authors:  P Picard; D Regoli; R Couture
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.